Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.30
Handel nachbörslich:
.26
0.26
+
Altamira Therapeutics Ltd Aktie (CYTO) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025 - GlobeNewswire
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on - Bluefield Daily Telegraph
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan - ACCESS Newswire
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray - ACCESS Newswire
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis - ACCESS Newswire
Altamira Therapeutics Amends Revenue Sharing Agreement with Altamira Medica - TipRanks
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent - GlobeNewswire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets - ACCESS Newswire
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program - ACCESS Newswire
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19 - ACCESS Newswire
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability - ACCESS Newswire
Auris Medical and King's College London Extend Tinnitus Collaboration -February 22, 2017 at 08:02 am EST - Marketscreener.com
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 - ACCESS Newswire
Altamira Therapeutics Ltd. Announces Collaboration on Radiopharmaceutical Targeting Strategies - Marketscreener.com
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies - GlobeNewswire
Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire
Altamira Therapeutics achieves nanoparticle-based delivery of circular mRNA - BioWorld Online
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - The Manila Times
Altamira Therapeutics Ltd. Announces Successful Nanoparticle-Based Delivery of Circular RNA - Marketscreener.com
Nasdaq de-lists Altamira shares - Royal Gazette
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Marketscreener.com
Altamira Therapeutics Moves to OTCQB After Nasdaq Delisting Over Minimum Bid Requirements - StockTitan
Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 1.3% – Here’s What Happened - Defense World
Loud and clear: Sound Pharma has phase III success in Meniere’s - BioWorld MedTech
CYTO stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com South Africa
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Advancements in Sensorineural Hearing Loss Clinical Trial - GlobeNewswire
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics Provides Update on Nasdaq Listing - GlobeNewswire
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com UK
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Nuance Pharma expands distribution of nasal spray Bentrio in East and South East Asia - BioSpectrum Asia
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia - GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - StockTitan
Altamira’s Bentrio nasal spray tests successfully - Royal Gazette | Bermuda
Bentrio nasal spray clears WADA substance test - Investing.com
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models - GlobeNewswire
Altamira’s drug-delivering nanoparticles could treat AAA - Clinical Trials Arena
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles - GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - GlobeNewswire
Altamira Therapeutics Provides Business Update - GlobeNewswire
What's Going On With Altamira Therapeutics Stock? - Benzinga
AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial - Wiley Online Library
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 - GlobeNewswire
Altamira Therapeutics and Univercells explore use of nanoparticle platform to deliver mRNA vaccines - BioWorld Online
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines - GlobeNewswire
2023 gainers and losers: Positive trial outcomes and M&As propel biopharma stocks to strong finish - BioWorld MedTech
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):